Compare Citius Pharmaceuticals Inc (CTXR) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Delta Air Lines, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Delta Air Lines, Inc. trades at $85.76 (market cap $56.23B). The key difference: Delta Air Lines, Inc. is far larger — about 3840.8× Citius Pharmaceuticals Inc's market cap, and Delta Air Lines, Inc. pays a 0.91% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | DAL | |
|---|---|---|
Market Cap | $14.64M | $56.23B |
Sector | Health | Industrials |
52-Week High | $1.82 | $93.66 |
52-Week Low | $0.53 | $51.15 |
Enterprise Value | $10.86M | $71.55B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Delta Air Lines (DAL) trades at $86.19, down 1.37% on the day, with a bullish technical outlook supported by strong earnings beats and positive analyst sentiment. The stock shows solid fundamentals with a P/E of 14.29 and net income margin of 5.78%, while recent news highlights premium demand resilience and AI-driven customer satisfaction improvements. Cash flow trends have strengthened, with net cash flow turning positive in 2025 at $1.08 billion.
The outlook remains favorable with an 81.82% analyst buy rating and a $108.27 consensus price target implying 26% upside. Key risks include fuel cost volatility and competitive pressures, but strong institutional support and consistent earnings performance underpin potential for continued growth amid stable travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
